La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Johnson & Johnson a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Johnson & Johnson..

Johnson & Johnson (NYSE:JNJ) Azioni, Catena delle Opzioni

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Jim Cramer

Equities

Markets

ABBV

L&#39;analisi sulle nuove dinamiche di mercato evidenzia le sfide per gli investitori tra sicurezza, volatilità e strategie di rendimento.

Obbligazioni vs. azioni: Jim Cramer spiega dove sono i rendimenti migliori

Trump shutterstock_2551951959

News

HYMTF

NVDA

SFTBF

L&#39;amministrazione celebra gli investimenti privati con i leader aziendali globali, in un contesto di incertezza sulle politiche commerciali.

Trump riunisce i CEO (Nvidia, J&amp;J, Toyota) per l&#39;evento &#34;Investing in America&#34;

Johnson & Johnson Inc. JNJ

Analyst Color

Earnings Beats

Reiteration

Analyst Ratings

Il colosso farmaceutico supera le stime sugli utili trimestrali ma il titolo resta cauto. Punti di forza e debolezze dai conti.

Investire in JNJ? Cosa dicono i risultati del Q1 e le analisi di Goldman, RBC e Guggenheim

https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-the-european-medicines-agency-seeking-indication-extension-of-akeega-niraparib-and-abiraterone-acetate-dual-action-tablet-for-the-treatment-of-adult-patients-with-metastatic-hormone-sensitive-prostate-cancer-and-hrr-gene-alterations#:~:text=BEERSE%2C%20BELGIUM%20(3%20July%202025,or%20prednisolone%20for%20the%20treatment

Biotech

Global

General

Johnson & Johnson Submits Application To The European Medicines Agency Seeking Indication Extension Of AKEEGA For The Treatment Of Adult Patients With Metastatic Hormone-Sensitive Prostate Cancer And HRR Gene Alterations

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$157.50</td>
<td>$94.8K</td>
<td>1.5K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/11/25</td>
<td>$30.00</td>
<td>$25.7K</td>
<td>980</td>
<td>1.0K</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$35.00</td>
<td>$29.5K</td>
<td>10</td>
<td>899</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$307.50</td>
<td>$37.3K</td>
<td>1.1K</td>
<td>437</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$20.00</td>
<td>$37.7K</td>
<td>1.0K</td>
<td>431</td>
</tr>
<tr>
<td>PRME</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$27.5K</td>
<td>24</td>
<td>100</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$60.00</td>
<td>$161.0K</td>
<td>827</td>
<td>100</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.00</td>
<td>$46.7K</td>
<td>14.6K</td>
<td>67</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$75.00</td>
<td>$26.5K</td>
<td>387</td>
<td>61</td>
</tr>
<tr>
<td>ELV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$340.00</td>
<td>$90.7K</td>
<td>11</td>
<td>56</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on July 18, 2025. Parties traded 465 contract(s) at a $157.50 strike. The total cost received by the writing party (or parties) was $94.8K, with a price of $204.0 per contract. There were 1504 open contracts at this strike prior to today, and today 1579 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on July 11, 2025. This event was a transfer of 211 contract(s) at a $30.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.7K, with a price of $122.0 per contract. There were 980 open contracts at this strike prior to today, and today 1094 contract(s) were bought and sold. 
• Regarding CNC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), we observe a call option sweep with bullish sentiment. It expires in 198 day(s) on January 16, 2026. Parties traded 50 contract(s) at a $35.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $29.5K, with a price of $590.0 per contract. There were 10 open contracts at this strike prior to today, and today 899 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bearish, expiring in 16 day(s) on July 18, 2025. This event was a transfer of 65 contract(s) at a $307.50 strike. The total cost received by the writing party (or parties) was $37.3K, with a price of $575.0 per contract. There were 1172 open contracts at this strike prior to today, and today 437 contract(s) were bought and sold. 
• For SRPT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), we notice a put option trade that happens to be bearish, expiring in 142 day(s) on November 21, 2025. This event was a transfer of 65 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $37.7K, with a price of $580.0 per contract. There were 1022 open contracts at this strike prior to today, and today 431 contract(s) were bought and sold. 
• For PRME (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on October 17, 2025. This event was a transfer of 100 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $27.5K, with a price of $275.0 per contract. There were 24 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option trade that happens to be bullish, expiring in 898 day(s) on December 17, 2027. This event was a transfer of 100 contract(s) at a $60.00 strike. The total cost received by the writing party (or parties) was $161.0K, with a price of $1610.0 per contract. There were 827 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 198 day(s) on January 16, 2026. Parties traded 10 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $46.7K, with a price of $4673.0 per contract. There were 14663 open contracts at this strike prior to today, and today 67 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bullish sentiment. It expires in 142 day(s) on November 21, 2025. Parties traded 45 contract(s) at a $75.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $590.0 per contract. There were 387 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• Regarding ELV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), we observe a call option sweep with bearish sentiment. It expires in 79 day(s) on September 19, 2025. Parties traded 24 contract(s) at a $340.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $90.7K, with a price of $3768.0 per contract. There were 11 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

PRME

SRPT

10 Health Care Stocks With Whale Alerts In Today's Session

<a href="https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-01/rfk-jr-vows-overhaul-of-lawsuit-sparing-vaccine-injury-program?embedded-checkout=true</a>

BNTX

'RFK Jr. Vows Overhaul of Lawsuit-Sparing Vaccine Injury Program'- Bloomberg

The <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">Dow Jones Industrial Average</a> was up around 4% in the first half of 2025, with 21 of the 30 components positive year-to-date through the first six months.
The index, which contains a diverse basket of stocks across sectors, offers many dividend stocks, with some having high yields for investors.
What Happened: When looking <a href="https://www.benzinga.com/dividends">for dividend stocks</a>, the Dow Jones Industrial Average is one place with the index having a basket of what are considered blue-chip American companies.
The 30 index components have strong track records of revenue and earnings growth, and in many cases, a long history of paying dividends and raising the dividend amounts.
While investors can buy an ETF like the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), which tracks the entire index, another option is to buy the &#8220;Dogs of the Dow.&#8221;
The "Dogs of the Dow" is a popular strategy that often coincides with the beaten-down stocks of the index which also offer high dividend payouts.
Here are the current top-yielding dividend stocks in the Dow Jones Industrial Average after the first six months of 2025.
<ol class="wp-block-list">
<li>Verizon Communications Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>): 6.3%</li>
<li>Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): 4.8%</li>
<li>Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): 4.1%</li>
<li>Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): 3.4%</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>): 3.4%</li>
<li>Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): 2.9%</li>
<li>UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>): 2.8%</li>
<li>Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>): 2.7%</li>
<li>Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>): 2.5%</li>
<li>McDonald's Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): 2.4%</li>
</ol>
In the Dow Jones Industrial Average, 28 of the 30 stocks pay out dividends. The average dividend yield of the 30 companies is 2% with the 10 highest averaging a yield of 3.5%.
Twenty of the 30 stocks in the index pay out at least a 1% dividend yield based on current stock prices.
Read Also: <a href="https://www.benzinga.com/markets/large-cap/25/07/46200141/dow-jones-2025-first-half-scoreboard-top-10-winners-losers-where-do-nvidia-apple-stock-rank">Dow Jones 2025 First Half Scoreboard: Top 10 Winners, Losers — Where Do Nvidia, Apple Stock Rank?</a>
Why It's Important: Along with stock price gains, dividends can be a nice form of consistent growth for companies and investors.
Investors can choose to collect dividend yield and put the capital to work in other stocks, or use it as income for other investments or spending. Investors can also reinvest the dividends back into the companies from which they got dividends.
Over a long period of time, dividend stocks can offer strong returns for investors with yields sometimes outpacing the returns of the overall stock market or other asset classes such as bonds and treasuries.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/best-monthly-dividend-stocks">Best Monthly Dividend Stocks</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Education

Dividends

Trading Ideas

AMGN

SPDR Dow Jones Industrial Average ETF Trust

Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%

A federal court has sided with the U.S. Department of Health and Human Services (HHS), rejecting Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) effort to reshape its participation in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">340B Drug Pricing Program</a>.
The ruling comes after months of legal back-and-forth following Johnson &amp; Johnson's proposal to shift from upfront drug discounts to a rebate model—an approach the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to" rel="noreferrer noopener">agency never formally approved</a>.
The dispute centers on the 340B Program, a federal initiative requiring pharmaceutical manufacturers that participate in Medicaid and Medicare Part B to sell outpatient drugs at reduced prices to certain healthcare providers, including hospitals and clinics that serve low-income and rural populations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46166652/fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers" rel="noreferrer noopener">FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers</a>
Johnson &amp; Johnson, a long-time participant in the program, initiated litigation in November 2024 after the Health Resources and Services Administration (HRSA) declined to approve its proposed rebate structure.
Under Johnson &amp; Johnson&#8217;s plan, covered entities would pay the full list price for certain drugs and receive rebates later.
The company contacted HRSA in June 2024 to outline the plan, but the agency made clear it had not given the green light.
Despite this, Johnson &amp; Johnson <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">proceeded to file suit</a> against HHS, HRSA, and their respective leadership, arguing that HRSA's rejection was arbitrary under the Administrative Procedure Act (APA).
In January 2025, UMass Memorial Medical Center, Genesis HealthCare System, and the advocacy group 340B Health were granted permission to intervene in the case as defendants, <a target="_blank" href="https://sponsors.aha.org/rs/710-ZLL-651/images/20250627_340B_045111473084.pdf?version=0" rel="noreferrer noopener">arguing</a> the rebate model would undercut the purpose of the 340B program and impose financial strain on safety-net providers.
Johnson &amp; Johnson subsequently moved for summary judgment on its single APA claim, while both the federal agencies and the intervenors filed cross-motions. The court has now denied Johnson &amp; Johnson's motion and ruled in favor of HHS and the intervenors, concluding that the agency acted within its authority and did not violate administrative law in rejecting the rebate plan.
The decision marks a significant win for hospitals and healthcare groups reliant on upfront 340B pricing to manage drug costs, especially for vulnerable patient populations. It also affirms HRSA's oversight authority in maintaining the integrity of the 340B program.
In sum, based on the plain and unambiguous language of the 340B statute, and supported by its purpose and history, HRSA has the authority to "provide" for discounts, rebates, or both. This conclusion defeats J&amp;J's claim that HRSA lacked the authority to require prior approval of J&amp;J's rebate model, the lawsuit alleged.
Price Action: JNJ stock is up 0.10% at $152.91 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46021366/mark-cuban-corrects-elizabeth-warren-as-she-slams-jnj-pfe-for-higher-prices-and-zero-taxes-on-big-pharma-pbms-corrupt-healthcare" target="_blank" rel="noreferrer noopener">Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: &#8216;PBMs Corrupt Healthcare&#8217;</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Legal

Johnson & Johnson's Drug Discount Plan Gets Thrown Out In Court

The U.S. Food and Drug Administration (FDA) announced on Friday that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">CAR T cell immunotherapies</a>.&nbsp;
These products are gene therapies currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma.
&#8220;The FDA has taken the bold step to remove the Risk Evaluation and Mitigation Strategy requirement from giving CAR T therapies. REMS is a useful safety system, but reevaluation over time helps inform whether a REMS is still needed to ensure that the benefits of a product outweigh its risks,&#8221;&nbsp;said FDA Vinay Prasad, Chief Medical and Scientific Officer and Director, Center for Biologics Evaluation and Research.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46144447/fda-eases-rules-for-bristol-myers-cell-therapies-for-blood-cancers" rel="noreferrer noopener">FDA Eases Rules For Bristol Myers&#8217; Cell Therapies For Blood Cancers</a>
&#8220;Eliminating the REMS that is no longer needed also expedites the delivery of potentially curative treatments to patients and reduces the burden on providers,&#8221; he added.
A REMS is a safety <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor" rel="noreferrer noopener">program</a> that the FDA can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.
The FDA determined that the approved REMS for the f<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se" rel="noreferrer noopener">ollowing products should be eliminated</a> because a REMS is no longer necessary to ensure that the benefits of the autologous CAR T cell immunotherapies outweigh their risks.&nbsp;
The products affected by this change include Bristol Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel), Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Carvykti (ciltacabtagene autoleucel), Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Kymriah (tisagenlecleucel), and Gilead Science Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).
The elimination of REMS for the above products removes the requirements that hospitals and their associated clinics that dispense products must be specially certified and have on-site, immediate access to tocilizumab.
&#8220;Continuous monitoring and assessment of the safety of all biological products, including the CAR T cell immunotherapies, is an FDA priority and we remain committed to informing the public when we learn new information about these products,&#8221; the FDA said in a press release.
As per a <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor" rel="noreferrer noopener">safety</a> statement on Thursday, the regulator also reduced its requirement that patients remain near the facility where they received treatment to two weeks. The agency also removed its advice to patients to avoid driving for two weeks following product administration.
Commenting on the development and accessibility of CAR T-cell therapies, William Blair said, &#8220;Overall, we view the removal of the REMS program for CAR-T cell therapies as a positive development for the space, as it supports the notion that the FDA is working to minimize red tape and increase access to potentially curative treatments for patients. We also believe the removal of the REMS requirements could increase access and use of these therapies in the community settings.&#8221;
Analyst Sami Corwin said the update also suggests there will likely be no REMS requirements for CD19 and BCMA autologous CAR-T cell therapies approved in the future, such as Arcellx, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLX#NASDAQ">ACLX</a>) anito-cel.
Moreover, Corwin highlighted the positive implications for companies developing CAR T-cell therapies for autoimmune diseases, such as Autolus Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>), Bristol-Myers, and Cabaletta Bio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>), &#8220;given that the safety profile is more tolerable than in oncology.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46163176/microsoft-stock-could-soar-44-on-ai-boom-analyst-says-but-theres-a-catch" target="_blank" rel="noreferrer noopener">Microsoft Stock Could Soar 44% On AI Boom, Analyst Says — But There&#8217;s A Catch</a></li>
</ul>
Photo by Tada Images via Shutterstock

ACLX

AUTL

CABA

GILD

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers

<a href="https://www.youtube.com/watch?v=z-16fImZoEc">https://www.youtube.com/watch?v=z-16fImZoEc</a>
&nbsp;

NVAX

U.S. CDC Advisory Panel Votes 5-1 In Favor Of Children 18 Years & Younger Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of Pregnant Women Receiving Seasonal Flu Vaccine Only In Single Dose Forms That Are Free From Thimerosal; Of All Adults Receiving Seasonal Flu Shot Only In Single Dose Forms That Are Free From Thimerosal

U.S. CDC Vaccine Advisory Panel Votes 7-0 In Favor Of Adding Preventive RSV Therapies To Vaccines For Children Resolution

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY&#x2122; (nipocalimab-aahu) versus other approved FcRn blockers in adults with generalized myasthenia gravis (gMG). These data, featured at the European Academy of Neurology (EAN) 2025 Congress in Helsinki, Finland, are among the 11 abstracts Johnson &amp; Johnson&nbsp;is presenting.
&nbsp;
Based on the ITC, which included the pivotal Phase 3 Vivacity-MG3 study data, IMAAVY showed comparable onset of symptom relief at Week 1 and showed consistent and sustained disease control with greater or statistically significant improvement of MG-ADLa scores versus the published Phase 3 data of other marketed FcRn blockers at several timepoints up to 24 weeksb of treatment.1 Results were consistent across multiple ITC methodsc.
<ul>
<li>Population-adjusted&nbsp;ITCs without a common control exhibited significantly greater mean improvements in MG-ADL scores favoring IMAAVY over other FcRn blockers, at Weeks 8-24d versus one comparator and at Weeks 10-14d versus another comparator.1</li>
<li>In placebo-adjusted&nbsp;ITCs, IMAAVY was associated with numerically greater efficacy versus one treatment comparator at Weeks 8e and 18-24e and versus another at Weeks 10-14e, with statistical significance at Weeks 10f and 12f</li>
</ul>

Johnson & Johnson Reports Data Showing IMAAVY Controls Myasthenia Gravis Symptoms Better Than Rivals

Donald Trump Jr. has joined billionaire entrepreneur Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren (D-Mass.)&#8217;s approach to healthcare pricing.
Despite their political differences, Trump Jr. and Cuban found a common point of contention in Warren&#8217;s healthcare pricing strategy. They criticized the senator for not addressing&nbsp;the role of pharmacy benefit&nbsp;managers (PBMs) in escalating drug costs.
Warren had previously argued&nbsp;that the tax system was&nbsp;&#8220;rigged&#8221;&nbsp;because large pharmaceutical companies like&nbsp;Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) often escape federal taxes while charging exorbitant prices for their drugs. 
She wrote on X saying that the "highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Big Pharma companies like Johnson &amp; Johnson and Pfizer charge Americans the highest drug prices in the WORLD while often paying ZERO dollars in federal taxes themselves. Why? Because our tax system is rigged. Now, Republicans want to make it worse. I&#39;m fighting back. <a href="https://t.co/k7dFrXBneX">pic.twitter.com/k7dFrXBneX</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1935443373487440373?ref_src=twsrc%5Etfw">June 18, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cuban countered this by stating that PBMs, not pharmaceutical companies, are the ones controlling and manipulating drug pricing.
Also Read: <a href="https://www.benzinga.com/news/25/01/43245984/cuban-on-musk-i-have-no-problem-throwing-elon-under-the-bus-but-ill-save-it-for-when-its-truly-deser">Cuban on Musk: &#8216;I Have No Problem Throwing Elon Under the Bus, but I&#8217;ll Save It for When It&#8217;s Truly Deserved&#8217;</a>
Trump Jr. publicly supported Cuban&#8217;s viewpoint on X, despite Cuban&#8217;s well-known opposition to President Trump. This unexpected agreement highlights the growing concern over the role of PBMs in healthcare pricing.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Didn't think I'd be RTing Mark for a while, but he's 100% right on this issue. <a href="https://t.co/ofraK5IFQk">https://t.co/ofraK5IFQk</a>
&mdash; Donald Trump Jr. (@DonaldJTrumpJr) <a href="https://twitter.com/DonaldJTrumpJr/status/1935817600891601345?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
PBMs have been facing increasing scrutiny from federal regulators and lawmakers due to their influence on healthcare pricing. 
In 2020, the Federal Trade Commission released a report criticizing PBMs for imposing unfair terms on independent pharmacies, thereby favoring large corporate pharmacies like&nbsp;CVS&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
The public criticism from Trump Jr. and Cuban underscores the growing debate over the role of PBMs in healthcare pricing. 
Warren&#8217;s focus on pharmaceutical companies, while not entirely misplaced, overlooks the significant influence of PBMs in determining drug prices.
The Federal Trade Commission&#8217;s report from last year further highlights the need for regulatory scrutiny of PBMs. As the debate continues, it remains to be seen how lawmakers will address the issue of healthcare pricing and the role of PBMs in the future.
Read Next
<a href="https://www.benzinga.com/news/politics/25/06/45829489/mark-cuban-reacts-to-elon-musk-donald-trump-feud">Mark Cuban Reacts to Elon Musk-Donald Trump Feud</a>
Image: Shutterstock/lev radin

Politics

Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing

Whales with a lot of money to spend have taken a noticeably bearish stance on Johnson &amp; Johnson.
Looking at options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $1,337,900 and 2, calls, for a total amount of $123,232.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $145.0 to $160.0 for Johnson &amp; Johnson during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Johnson &amp; Johnson options trades today is 3709.43 with a total volume of 4,332.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Johnson &amp; Johnson's big money trades within a strike price range of $145.0 to $160.0 over the last 30 days.
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750446093_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.5</td>
<td>$9.85</td>
<td>$10.25</td>
<td>$160.00</td>
<td>$809.7K</td>
<td>4.0K</td>
<td>790</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.25</td>
<td>$3.05</td>
<td>$3.25</td>
<td>$150.00</td>
<td>$256.7K</td>
<td>6.3K</td>
<td>822</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$8.95</td>
<td>$8.9</td>
<td>$8.95</td>
<td>$145.00</td>
<td>$80.5K</td>
<td>2.1K</td>
<td>90</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$10.9</td>
<td>$10.5</td>
<td>$10.9</td>
<td>$160.00</td>
<td>$73.0K</td>
<td>4.0K</td>
<td>1.1K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.7</td>
<td>$6.55</td>
<td>$6.55</td>
<td>$155.00</td>
<td>$65.5K</td>
<td>4.1K</td>
<td>130</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 4,769,606, with JNJ's price down by -0.69%, positioned at $149.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 26 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $181.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $181. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Johnson & Johnson Unusual Options Activity For June 20

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices.
What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (PBMs) and Big Pharma's tax practices, with the Senate poised to address reform amid rising public scrutiny.
Enter Cuban, the Dallas Mavericks owner and founder of Cost Plus Drugs, who fired back with a pointed correction.
In a post quoting Warren, Cuban argued that PBMs—not Big Pharma—are the true culprits behind inflated drug prices.
&#8220;PBMs corrupt healthcare,&#8221; he wrote, explaining that these intermediaries control formularies and manipulate prices to maximize rebate revenue, with <a href="https://www.benzinga.com/25/05/45487788/trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-and-pricing-distortion">three major PBMs</a> negotiating over 90% of rebates for commercial insurance plans. 
Warren, in her post, had blamed pharmaceutical giants like Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) for charging Americans the &#8220;highest drug prices in the world&#8221; while paying &#8220;zero dollars in federal taxes.&#8221;
Citing data from her Senate Finance Committee role, Warren highlighted how these companies, alongside AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), have exploited tax loopholes from the 2017 Tax Cuts and Jobs Act to shield billions in profits.
&#8220;Republicans want to make it worse. I&#8217;m fighting back,&#8221; she declared, sharing <a href="https://www.cnbc.com/2025/06/17/pfizer-merck-jj-others-face-scrutiny-over-tax-loophole-extension.html">a</a> CNBC headline and urging action against what she calls a &#8220;rigged tax system.&#8221; 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No. It&#39;s because PBMs corrupt healthcare. Big Pharma wishes they could set their own pricing. They don&#39;t. PBMs control formularies and manipulate prices, in exchange for providing pharma access to patients. It&#39;s how they maximize rebate revenue. In fact, 3 PBMs NEGOTIATE… <a href="https://t.co/GpN4mnzvOM">https://t.co/GpN4mnzvOM</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1935705831930298562?ref_src=twsrc%5Etfw">June 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46013679/dan-ives-says-market-is-massively-underestimating-this-ai-play-urges-investors-to-look-beyong-mag-7">Dan Ives Says Market Is ‘Massively Underestimating' This AI Play, Urges Investors To Look Beyond Mag 7</a>
Why It Matters: Cuban has been a c<a href="https://www.benzinga.com/personal-finance/25/04/44674382/mark-cuban-says-big-insurance-companies-and-pbms-control-healthcare-costs-everyone-has-to-kiss-their-a-and-accept-the-complications">ritic of the healthcare system</a>, saying that it should be simple. According to him, it&#8217;s become overly complicated by big insurance companies and PBMs.
These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
He blames PBMs for lack of transparency, inflated specialty drug prices, rebate distortion, formulary restrictions, and &#8220;Sh–ing on&#8221; on independent pharmacies.
Some significant firms engaged in the PBM business listed in the U.S. include;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</td>
<td>51.15%</td>
<td>9.57%</td>
</tr>
<tr>
<td>Cigna Group. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>14.54%</td>
<td>-6.95%</td>
</tr>
<tr>
<td>UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td>-39.11%</td>
<td>-36.60%</td>
</tr>
</tbody>
</table>
</figure>
Meanwhile, here is how some pharmaceutical sector ETFs have performed;
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>1.69%</td>
<td>-4.48%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>-0.49%</td>
<td>-1.85%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>-3.23%</td>
<td>-1.64%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-4.06%</td>
<td>2.61%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>20.55%</td>
<td>22.94%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-5.44%</td>
<td>-6.27%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-23.49%</td>
<td>-14.63%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were mixed in premarket on Friday. The SPY was down 0.30% at $595.67, while the QQQ was 0.015% higher at $529.07, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46016347/this-stock-just-popped-30-in-5-days-now-expert-says-it-looks-potentially-explosive">This Stock Just Popped 30% In 5 Days — Now Expert Says It ‘Looks Potentially Explosive'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Insurance

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'

Jury concludes J&amp;J concealed the danger of its asbestos-laced talcum powder that caused woman's cancer
A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) talcum powder products.
The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer.
During the trial, the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdobslegal.com%2F&amp;esheet=54279382&amp;newsitemid=20250618099844&amp;lan=en-US&amp;anchor=Dean+Omar+Branham+Shirley&amp;index=1&amp;md5=d9fd59b911b8494899fa30004c35d027">Dean Omar Branham Shirley</a> legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson &amp; Johnson had internal knowledge of asbestos in its talc supply dating back decades yet continued to market the products as safe for daily use.
J&amp;J ceased production and sale of all products containing talc in the United States in 2020. Ms. Paluzzi, a lifelong user of the company's Baby Powder on herself and her children, was diagnosed with mesothelioma in 2021.

Johnson & Johnson Found Liable In Talc Cancer Case; Jury Awards $8M To Massachusetts Resident

<a href="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use" title="https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use">https://www.bloomberg.com/news/articles/2025-06-18/rfk-jr-weighs-review-of-dozens-of-shots-citing-aluminum-use</a>

'RFK Jr. Weighs Review of Dozens of Shots, Citing Aluminum Use' - Bloomberg News

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has fallen 15.79% since its last report. The company recently reported that it has 19.22 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.21 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750183231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.04%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Johnson & Johnson's Recent Short Interest

<a href="https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease" title="https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease">https://www.jnj.com/media-center/press-releases/johnson-johnson-seeks-u-s-fda-approval-of-stelara-ustekinumab-for-the-treatment-of-pediatric-crohns-disease</a>

Johnson & Johnson seeks U.S. FDA Approval Of STELARA For The Treatment Of Pediatric Crohn's Disease; Supported By 52-Week Data From The Phase 3UNITI-Jr Study, Submission Aims To Expand STELARA Indication To Treat Children Two Years Of Age And Older

<ul>
<li>Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA</li>
<li>Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs</li>
</ul>

Reported Sunday, Johnson & Johnson's TALVEY And TECVAYLI Investigational Combination Shows 78.9% Response Rate And Deep Durability In Heavily Pretreated Multiple Myeloma With Extramedullary Disease

Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease
75-80% complete response rate among evaluable patients at the recommended Phase 2 dose&nbsp;
MILAN, June 13, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findings demonstrate the potential of JNJ-4496 in the treatment of patients with R/R LBCL, including R/R diffuse large B-cell lymphoma (DLBCL) – the most common type of aggressive lymphoma, a blood cancer that originates in the lymphatic system.1,2 These data were presented as an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4448366-1&amp;h=2997833116&amp;u=https%3A%2F%2Fehaweb.org%2Fconnect-network%2Feha2025-congress&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a>&nbsp;(<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4448366-1&amp;h=3124684094&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159316%2Fmatthew.ku.a.global.phase.1b.study.of.jnj-90014496.a.cd19.cd20.bi-specific.html%3Ff%3Dlisting%253D0%252Abrowseby%253D8%252Asortby%253D1%252Asearch%253DJNJ-90014496&amp;a=Abstract+%23S239">Abstract #S239</a>).1
JNJ-4496, formerly known as C-CAR039, is a dual-targeting CAR T designed to bind to both CD19 and CD20 antigens — two cell surface proteins commonly expressed on malignant B-cells. This design, including a 4-1BB costimulatory domain, is intended to enhance binding strength and persistence, also potentially addressing common mechanisms of resistance in relapsed or refractory disease.
In the Phase 1b dose confirmation study (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4448366-1&amp;h=2043334395&amp;u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05421663%3Fintr%3DJNJ-90014496%26rank%3D1&amp;a=NCT05421663">NCT05421663</a>) in patients with R/R LBCL, data at the recommended Phase 2 dose (RP2D) were reported in patients with a median follow-up of 4 months. Results informed a RP2D of JNJ-4496 at 75 million CAR+ T-cells. Among the 22 patients in the RP2D group where efficacy was assessed, those who received one prior line of therapy (n=10) had an objective response rate (ORR) of 100 percent and a complete response rate (CRR) of 80 percent (95 percent confidence interval (CI), 69, 100). In the patients who had received two or more prior lines of therapy (n=12), the ORR was 92 percent and the CRR was 75 percent (95 percent CI, 62, 100).1

Johnson & Johnson's Dual-Targeting CD19/CD20 CAR T Therapy Phase 1b Study, Achieves 75% - 80% Complete Response Rate In Relapsed Or Refractory Large B-Cell Lymphoma Patients, Demonstrating Safety Profile At Recommended Phase 2 Dose

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new Phase 1b data showing encouraging&nbsp;antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML.1 The results were featured in an oral presentation at the&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447496-1&amp;h=3957088323&amp;u=https%3A%2F%2Fehaweb.org%2Fconnect-network%2Feha2025-congress&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a>&nbsp;(<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4447496-1&amp;h=3103175932&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159214%2Fandrew.h.wei.rp2d.determination.of.bleximenib.in.combination.with.ven2Baza.html%3Ff%3Dlisting%253D0%252Abrowseby%253D8%252Asortby%253D1%252Asearch%253Dbleximenib&amp;a=S137">S137</a>).

Johnson & Johnson Announces Bleximenib, Investigational Selective Menin Inhibitor, Shows Potential As Combination Therapy For Treatment Of Relapsed Or Refractory AML And Newly Diagnosed, Intensive Chemo-Ineligible AML

TREMFYA&nbsp;&#xAE;&nbsp;demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study
More than 40% of TREMFYA&#xAE;-treated patients across both dose groups achieved ACR50&nbsp;at Week 24
Improvement in both joint and skin symptoms reinforce TREMFYA&#xAE; as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis
BARCELONA, June 11, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced findings from the Phase 3b APEX study showing that TREMFYA&#xAE; (guselkumab) significantly reduced both signs and symptoms of active psoriatic arthritis (PsA) and inhibited progression of joint structural damage at 24 weeks compared to placebo.1 These data from a late-breaking abstract are among the 30 oral and poster presentations Johnson &amp; Johnson is highlighting at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress.
In the Phase 3b APEX study, TREMFYA&#xAE; significantly inhibited progression of joint structural damage, including joint erosions and space narrowing, in patients with active PsA at Week 24 as assessed by the PsA modified van der Heijde-Sharp (vdH-S) score. The mean change from baseline to Week 24 in the modified van der Heijde-Sharp (vdH-S) score was 0.55 and 0.54 for patients receiving TREMFYA&#xAE; every four weeks (Q4W) and every eight weeks (Q8W) respectively, compared with 1.35 in the placebo group (p=0.002 for Q4W and p&lt;0.001 for Q8W dosing versus placebo, respectively). In the two TREMFYA&#xAE; dose groups, 67% (Q4W) and 63% (Q8W) of patients experienced no radiographic progression, versus 53% in the placebo group.a,1

Johnson & Johnson's TREMFYA Reduces Joint Damage And Improves Psoriatic Arthritis Symptoms In Phase 3b APEX Study, With Over 40% Achieving ACR50 And Majority Showing No Radiographic Progression At 24 Weeks

Press Releases

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia

Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease

Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

Vicarious Surgical Announces Election of New Directors

GSAT

IRIX

MITK

RBOT

VXRT

RBC Capital

Leerink Partners

Barclays

Raymond James

Morgan Stanley

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

Johnson & Johnson (JNJ) Opzioni

Johnson & Johnson (NYSE:JNJ) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO